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Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, and
the biology of this cancer remains poorly understood. Recent evidence indicates that long non-coding RNAs
(lncRNAs) are found to be dysregulated in a variety of cancers, including HCC. Taurine Up-regulated Gene 1 (TUG1),
a 7.1-kb lncRNA, recruiting and binding to polycomb repressive complex 2 (PRC2), is found to be disregulated in
non-small cell lung carcinoma (NSCLC) and esophageal squamous cell carcinoma (ESCC). However, its clinical
significance and potential role in HCC remain unclear.
Methods and results: In this study, expression of TUG1 was analyzed in 77 HCC tissues and matched normal
tissues by using quantitative polymerase chain reaction (qPCR). TUG1 expression was up-regulated in HCC tissues
and the higher expression of TUG1 was significantly correlated with tumor size and Barcelona Clinic Liver
Cancer (BCLC) stage. Moreover, silencing of TUG1 expression inhibited HCC cell proliferation, colony formation,
tumorigenicity and induced apoptosis in HCC cell lines. We also found that TUG1 overexpression was induced by
nuclear transcription factor SP1 and TUG1 could epigeneticly repress Kruppel-like factor 2 (KLF2) transcription in
HCC cells by binding with PRC2 and recruiting it to KLF2 promoter region.
Conclusion: Our results suggest that lncRNA TUG1, as a growth regulator, may serve as a new diagnostic
biomarker and therapy target for HCC.
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Hepatocellular carcinoma (HCC) is the dominant histo-
logical type of primary liver cancer which accounts for
70–85 % of primary malignancies in liver, and HCC is the
third leading cause of cancer-related death worldwide [1].
While, half of these cases and deaths were estimated to
occur in China [2]. Generally, hepatocarcinogenesis is a
multistep process involving a number of genetic or epi-
genetic alterations that eventually result in the malignant
transformation of hepatocytes [3, 4]. There have been* Correspondence: yongqian_shu@163.com
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HCC and lots of therapeutic strategies have been im-
proved [5]. However, the 5-year overall survival rate
remains very poor and the biology of HCC remains poorly
understood. Therefore, the identification of the new bio-
markers for HCC and a detailed understanding of the
molecular mechanisms underlying hepatic carcinogenesis
will supply an arm for improving diagnosis and manage-
ment of human HCC.
MicroRNAs and long noncoding RNAs (lncRNAs) are
two major members of ncRNA family, and lots of studies
have demonstrated that miRNAs play critical roles in HCC
development [6]. For example, miR-331-3p could promote
HCC cells proliferation and EMT-mediated metastasis by
suppressiing PHLPP-mediated dephosphorylation of AKTis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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200 nucleotides without or with limit protein coding
ability [8–10], emerge as essential regulators in almost all
aspects of biology via regulation at chromatin organization,
transcriptional and post-transcriptional levels [11, 12]. Add-
itionally, a number of studies demonstrate that lncRNAs
play an important role in tumorigenesis, and their misex-
pression confers tumor initiation, cancer cells growth and
metastasis [13–15]. For example, lncRNA GAPLINC regu-
lates CD44-dependent cell invasiveness by acting as a
molecular decoy for miR211-3p and associates with poor
prognosis in gastric cancer [16]. Moreover, lncRNA-ATB
activated by TGF-β could promote the invasion -metastasis
cascade in HCC cells by binding IL-11 mRNA, autocrine
induction of IL-11 and triggering STAT3 signaling [17]. Al-
though, there has been a heavy focus on the ways that
lncRNAs contribute to cancers development, but their ab-
errant expression and functional roles in HCC development
and diagnosis are still not well documented.
LncRNA TUG1,a 7.1-kb lncRNA, was firstly detected in
a genomic screen for genes up-regulated in response to
taurine treatment of developing mouse retinal cells [18].
Recently, TUG1 was found to be generally downregulated
in NSCLC [19]. On the contrary,some studies showed that
TUG1 can promote the cell proliferation of ESCC [20],
urothelial carcinoma of the bladder [21] and osteosarcoma
[22]. However, the functional role and underlying mech-
anism of TUG1 in HCC remains unclear. Here we investi-
gated the relationship between TUG1 and HCC. We
found that TUG1 was up-regulated in HCC tissues than
that in corresponding non-tumor tissues and was related
to tumor size and BCLC stage. Moreover, we found that
TUG1 overexpression was induced by nuclear transcrip-
tion factor SP1 and TUG1 could regulate cell growth both
in vitro and in vivo via epigenetically silencing KLF2 by
binding to PRC2. Our results suggest that TUG1 overex-
pression was induced by nuclear transcription factor SP1
and TUG1 can regulate KLF2 expression in the epigenetic
level and facilitate the development of lncRNA-directed
diagnostics and therapeutics of HCC.
Results
TUG1 is up-regulated in hepatocellular carcinoma tissues
and is associated with tumor size and BCLC stage
The level of TUG1 was detected in 77 paired HCC tis-
sues and corresponding adjacent normal tissues by
qPCR, and normalized to GAPDH. The results showed
that TUG1 expression was significantly up-regulated in
61.04 % (47 of 77,fold≧1.5) cancerous tissues compared
with normal counterparts (P < 0.01) (Fig. 1a). To under-
stand the significance of TUG1 overexpression in HCC,
we investigated the potential associations between TUG1
expression and patients’ clinicopathological features. Clini-
copathological features of HCC patients were shown inTable 1. Noticeably, high TUG1 expression was signifi-
cantly correlated with tumor size (P = 0.003) and ad-
vanced BCLC stage (P < 0.01). However, TUG1 expression
was not associated with other parameters such as drinking
state (P = 0.531), age (P = 0.970), gender (p = 0.832), AFP
(P = 0.570), HBV (P = 0.533) and cirrosis (P = 0.378) in
HCC.TUG1 is up-regulated in HCC cell lines and could be
activiated by transcript factor SP1
To investigate the functional role of TUG1 in HCC cells,
qPCR was used to detect the expression of TUG1 in
three HCC cell lines. As shown in Fig. 1b, HCC cell lines
expressed higher levels of TUG1 compared with the nor-
mal hepatic epithelium cell line (L02). And we chose
HepG2 and Hep3B for next study. We performed bio-
informatics analysis and found that there are five SP1
binding sites in the TUG1 promoter region, which sug-
gest that SP1 could also regulate TUG1 transcription (as
shown in Table 2). In addition, over-expression of SP1
in HCC cells could up-regulate TUG1 expression, while
knockdown of SP1 in HCC cells could down-regulate
TUG1 expression (as shown in Fig. 1d-1o). ChIP assay
showed that SP1 could directly bind to TUG1 promoter
regions (as shown in Fig. 1c). Luciferase assay also showed
that SP1 could directly bind to TUG1 promoter regions.Knockdown of TUG1 inhibits HCC cell proliferation and
induces cell apoptosis in vitro
To investigate the potential role of TUG1 on HCC cells
proliferation, TUG1 siRNA was transfected into HepG2
and Hep3B cells. To ensure the efficiency of interference
and avoid off-target effects, we used two validated effect-
ive interference target sequence of TUG1, according to
Zhang’s study [19]. QPCR assays revealed that TUG1
expression was significantly reduced after transfection
with si-TUG1-1# and si-TUG1-2# (Fig. 2a). Then MTT
assay showed that knockdown of TUG1 expression
significantly inhibited cell proliferation both in HepG2
and Hep3B cells compared with control cells (Fig. 2b).
Similarly, the result of colony-formation assay revealed
that clonogenic survival was significantly decreased fol-
lowing inhibition of TUG1 in HepG2 and Hep3B cell
lines (Fig. 2c). Next, flow cytometric analysis was per-
formed to further examine whether the effect of TUG1
on proliferation of HCC cells by altering cell-cycle
progression or apoptosis. The results revealed that the
cell-cycle progression of HepG2/si-TUG1 and Hep3B/si-
TUG1 was significantly stalled at the G1–G0 phase
compared with cells transfected with si-NC (Fig. 2d). In
addition, knockdown of TUG1 could obviously induce
cell apoptosis (Fig. 2e).
Fig. 1 Relative TUG1 expression in HCC tissues and HCC cell lines and TUG1 was regulated by SP1. a Relative TUG1 expression in HCC tissues
(n = 77) compared with corresponding non-tumor tissues (n = 77). TUG1 expression was examined by qPCR and normalized to GAPDH expression.
Results were presented as ΔCT in tumor tissues relative to normal tissues. b Relative TUG1 expression levels of HCC cell lines (HepG2, Hep3B, MHCC-97H)
compared with that in the normal hepatic epithelium cell line (L02). c ChIP–qPCR of SP1 occupancy and binding in the TUG1 promoter in HepG2 and
Hep3B cells, and IgG as a negative control. d Luciferase reporter assay was performed by co-transfecting the TUG1 promoter fragment (pGL3-TUG1) or
deleted TUG1 promoter fragment with SP1 expression vector or an empty vector in HepG2 cells. e The SP1 expression level was determined by qPCR
when HepG2 cells transfected with si-SP1. f The TUG1 expression level was determined by qPCR when HepG2 cells transfected with si-SP1. g The SP1
expression level was determined by qPCR when Hep3B cells transfected with si-SP1. h The TUG1 expression level was determined by qPCR when Hep3B
cells transfected with si-SP1. i The SP1 expression level was determined by qPCR when HepG2 cells transfected with EGFP-SP1. j The TUG1 expression level
was determined by qPCR when HepG2 cells transfected with EGFP-SP1. k The SP1 expression level was determined by qPCR when Hep3B cells transfected
with EGFP-SP1. l The TUG1 expression level was determined by qPCR when Hep3B cells transfected with EGFP-SP1.m,n The SP1 protein expression level
was determined by Western blotting when HepG2/Hep3B cells transfected with si-SP1. o,p The SP1 protein expression level was determined by Western
blotting when HepG2/Hep3B cells transfected with EGFP-SP1
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Table 1 Correlation between TUG1 expression and
clinicopathological characteristics of HCC patients
Characteristics TUG1 P-value
High cases (No 47) Low cases (No 30)
Age (years) 0.970
< 50 19 12


















≦3 cm 7 13
3–5 cm 11 11
5–10 cm 26 6
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To further determine whether TUG1 affects tumorigen-
esis, we injected HepG2 cells transfected with either
empty vector or sh-TUG1 into male nude mice. In con-
sistent with in vitro results, tumor growth in sh-TUG1
group was obviously slower than that in the empty vec-
tor group (Fig. 3a). Up to 16 days after injection, theTable 2 Putative SP1-binding sites in the TUG1 promoter by JASPAR
Model ID Model name Score Relative score
MA0079.3 SP1 17.396 1.000002277
MA0079.3 SP1 12.216 0.934831947
MA0079.3 SP1 14.434 0.962736926
MA0079.3 SP1 11.184 0.921848205
MA0079.3 SP1 14.626 0.965152506average tumor weight in sh-TUG1 group (0.196 ±
0.092 g) was significantly lower than that in the control
group (0.582 ± 0.060 g) (P < 0.01) (Fig. 3b). qPCR ana-
lysis was performed to detect the average expression of
TUG1 in tumor tissues selected from mice (Fig. 3c). Re-
sults demonstrated that the average expression level of
TUG1 in sh-TUG1 group was lower than that in empty
group (Fig. 3d). Moreover, we found that the tumors de-
veloped from empty vector transfected cells showed a
stronger Ki-67 expression than that in tumors formed
from sh-TUG1 as detected by IHC analysis (Fig. 3e).
These data further supported the role of TUG1 in HCC
cell growth and proliferation.
TUG1 negatively regulates expression of KLF2
As previously reported, TUG1 could regulate HOXAB7
expression by binding with PRC2. In the present study,
we analysized the KLF2 gene expression in 77 paired
HCC tissues and corresponding adjacent normal tissues
by qPCR, and normalized to GAPDH. It showed that
KLF2 was downregulated in HCC and negatively related
to the expression of TUG1 by co-expression analysis (as
shown in Fig. 4a,b). And we further found that knock-
down of TUG1 expression could up-regulate both KLF2
mRNA and protein expression levels in HCC cells
(Fig. 4c-e). Moreover, knockdown of EZH2 or SUZ12
could also up-regulate KLF2 mRNA and protein expres-
sion levels in HCC cells (Fig. 4f-o). We examined the
TUG1 expression levels in HCC cell cytoplasm and nu-
cleus distribution, and the results showed that TUG1 ex-
pression is more located in nucleus (seen in Fig. 4p,q).
In addition, the results of RIP assays revealed that TUG1
could directly bind with PRC2 in HCC cells (seen in
Fig. 4r,s). And ChIP assays were performed to deter-
mine whether EZH2 could directly bind to KLF2 pro-
moter regions to silence KLF2 transcription. The results
showed that EZH2 can directly bind to KLF2 promoter
regions (616 bp), while knockdown of TUG1 expression
decreased its’ binding ability (seen in Fig. 4t,u). Then
qPCR analysis was performed to detect the average ex-
pression of KLF2 in tumor tissues selected from mice
(Fig. 4v). Results demonstrated that the average expression
levels of KLF2 in sh-TUG1 group was higher than that in
either empty group. Finally, we found that the tumors de-
veloped from sh-TUG1 transfected cells showed aStart End Strand Predicted site sequence
1395 1405 1 GCCCCGCCCCC
1571 1581 1 GTCCCTCCCCG
1888 1898 1 CTCCCGCCCCC
1894 1904 1 CCCCCGCCCTG
1965 1975 1 GTCCCGCCCCT
Fig. 2 Effects of knockdown of TUG1 on HCC cells viability and apoptosis in vitro. a,b The TUG1 expression level was determined by qPCR when
HepG2 and Hep3B cells transfected with si-TUG1. c,d MTT assays were used to determine the cell viability for si-TUG1-transfected HepG2 and
Hep3B cells. Values represented the mean ± s.d. from three independent experiments. e,f Colony-forming assays were conducted to determine
the proliferation of si-TUG1-transfected HepG2 and Hep3B cells. g,h Flow cytometry assays were performed to analysize the cell cycle progression
when HCC cells transfected with si-TUG1 24 h later. The bar chart represented the percentage of cells in G0/G1, S, or G2/M phase, as indicated.
i,j Flow cytometry assays were performed to analysis the cell apoptosis when HCC cells transfected with si-TUG1 48 h later. k,l PARP cleavage
protein via western blot after TUG1 depletion. *P < 0.05, **P < 0.01
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from empty vector as detected by IHC analysis (Fig. 4w).
These data indicated that KLF2 is an new TUG1 target
gene in HCC, and its’ expression can be silenced by EZH2
which is recruited by TUG1 to KLF2 promoter region and
mediated H3K27 trimethylation modification.
Over-expression of KLF2 impaires HCC cells proliferation
and induces cell apoptosis
To determine whether KLF2 involved in TUG1 medi-
ated increased HCC cells proliferation, we up-regulated
KLF2 expression in HCC cells by transfecting with a
FLAG-tagged KLF2 expression vector using the pCMV-
Tag2B vector (Stratagene, Santa Clara, CA, USA). The
qPCR results showed that KLF2 expression is signifi-
cantly up-regulated in pCMV-Tag2B-KLF2 transfected
HCC cells when compared with control cells (Fig. 5a).
Furthermore, MTT assays revealed that KLF2 over-
expression inhibited HCC cells growth, and flow cyto-
metric analysis indicated that increased KLF2 expression
resulted in HCC cells G0/G1 arrest and induced cellapoptosis (Fig. 5b-d). These datas suggest that KLF2
partly involved in HCC cells proliferation and apoptosis.
Moreover, to determine whether TUG1 regulate HCC cell
proliferation by repressing KLF2 expression, rescue assays
were performed. HepG2 cells were co-transfected with si-
TUG1 and si-KLF2, and which was shown to rescue the
decreased expression of TUG1 induced by knockdown of
KLF2 (Fig. 6d, e). The results of MTT and colony for-
mation assay results indicated that co-transfection
could partially rescue si-TUG1-impaired proliferation
in HepG2 cells (Fig. 6a, b, c). These data indicate that
TUG1 promotes HCC cell proliferation through the
down-regulation of KLF2 expression.
Discussion
In the past decade, the discovery of numerous lncRNAs
has dramatically altered our understanding of the biol-
ogy of complex diseases including cancers. Recently, lots
of studies have revealed that dysregulated expression of
lncRNAs in multiple cancers, which may pinpoint the
spectrum of cancer progression and predict patients’
Fig. 3 Effects of down-regulation of TUG1 on tumor growth in vivo. a Tumors from mice 16 days after injection of HepG2 cells stably transfected
with sh-TUG1 or empty vector. b The tumor volume was calculated every four days after injection of HepG2 cells stably transfected with sh-TUG1
or empty vector. Points, mean (n = 5); bars indicate S.D. c Tumor weights are represented as means of tumor weights ± s.d. d QPCR analysis of
TUG1 expression in tumor tissues formed from HepG2/sh-TUG1, HepG2/empty vector. e Tumors developed from sh-TUG1 transfected HepG2 cells
showed lower Ki-67 protein levels than tumors developed by control cells. Left: H & E staining; Right: immunostaining. *P < 0.05, **P < 0.01
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as an oncogenic lncRNA that associates with BMI1 and
represses p21 expression in cancer by a functional gen-
omic approach [25]. In HCC, HULC was the first
reported lncRNA that is specifically up-regulated [26]. A
number of lncRNAs, such as HULC [27] and LINC00974
[28] have been reported to be involved in HCC develop-
ment and progression. In this study, we found that
lncRNA TUG1 whose expression is significantly up-
regulated in HCC tissues compared with normal tissues.
Moreover, increased TUG1 expression was correlated with
HCC tumor size and BCLC stage, which suggests that
TUG1 may play a key role in HCC development and
progression.
Several recent studies indicated that lncRNA expres-
sion could also be regulated by some transcript factors
(TF), such as lincRNA-p21 expression can be regulated
by p53 [29] and TINCR by SP1 [30]. TUG1 expression
has been reported to be regulated by an key p53 [19];
however, we found that TUG1 expression could also be
regulated by another TF SP1 in HCC cells, which sug-
gests that one lncRNA may be simultaneously regulated
by multiple different transcript factors. As is known,
lncRNAs involved in cancer cells biological function,
and we found that knockdown of TUG1 could impair
HCC cells proliferation, invasion and induce cellapoptosis both in vitro and vivo. These data suggests
that lncRNA TUG1 contributes to HCC development
via regulation of cell proliferation and apoptosis.
TUG1 has been reported to regulate the expression of
HOXB7 in NSCLC [19]. However, we found that TUG1
could bind with both EZH2 and SUZ12 in HCC cells.
Furthermore, co-expression analysis indicated that KLF2
could be a new TUG1 downstream target, and knock-
down of TUG1, EZH2 and SUZ12 expression indeed
both up-regulated KLF2 expression levels in HCC cells.
In addition, ChIP assays also demonstrated that EZH2
could directly bind to KLF2 promoter region and inhib-
ition of TUG1 decreased its binding ability. Our results
indicated that TUG1 could repress KLF2 transcription
by binding with EZH2 and SUZ12 and recruitment of
PRC2 to the KLF2 gene locus in HCC cells.
The Kruppel-like factor (KLF) family transcription fac-
tors have been identified as suppressors or activators of
different genes in a cell type and promoter-dependent
manner [31, 32]. Recently, lines of evidence showed that
KLF members are emerging as tumor suppressors due to
their roles in the inhibition of proliferation, invasion and
induction of apoptosis [33]. As an member of KLF
family, KLF2 expression is inactivated or lost in several
cancers and possesses tumor-suppressor features medi-
ated by KRAS [34]. Moreover, there is evidence showed
Fig. 4 TUG1 could silence KLF2 expression. a KLF2 gene expression in HCC tissues (n = 77) compared with corresponding non-tumor tissues
(n = 77). KLF2 expression was examined by qPCR and normalized to GAPDH expression. Results were presented as ΔCT in tumor tissues relative to
normal tissues. b Co-expression analysis between TUG1 and KLF2. c The levels of KLF2 mRNA were detected by qPCR when HepG2 and Hep3B cells
transfected with si-TUG1 and results are expressed relative to the corresponding values for control cells. d,e The levels of KLF2 protein levels were
determined by Western Blotting when HepG2 cells transfected with si-TUG1. f,g The levels of EZH2 protein were detected by Western Blotting when
HepG2 and Hep3B cells transfected with si-EZH2 and results are expressed relative to the corresponding values for control cells. h The levels of KLF2
mRNA were detected by qPCR when HepG2 and Hep3B cells transfected with si-EZH2 and results are expressed relative to the corresponding values
for control cells. i,j The levels of EZH2 protein were detected by Western Blotting when HepG2 and Hep3B cells transfected with si-EZH2 and results
are expressed relative to the corresponding values for control cells. k,l The levels of SUZ12 protein levels were determined by Western Blotting when
HepG2 cells transfected with si-SUZ12.m The levels of KLF2 mRNA were detected by qPCR when HepG2 and Hep3B cells transfected with si-SUZ12
and results are expressed relative to the corresponding values for control cells. n,o The levels of KLF2 protein levels were determined by Western
Blotting when HepG2 cells transfected with si-SUZ12. p,q TUG1 expression levels in cell cytoplasm or nucleus of HCC cell lines Hep3B and HepG2 were
detected by qPCR. r,s RIP with rabbit monoclonal anti-EZH2, anti-SUZ12, anti-SNRNP70 and preimmune IgG from HepG2 and Hep3B cell extracts. RNA
levels in immunoprecipitates were determined by qPCR. Expression levels of TUG1 RNA were presented as fold enrichment in EZH2 and SUZ12 relative
to IgG immunoprecipitates; relative RNA levels of U1 snRNA in SNRNP70 relative to IgG immunoprecipitates were used as positive control. t,u ChIP–qPCR
of EZH2 occupancy and H3K27-3me binding in the KLF2 promoter in HepG2 cells, and IgG as a negative control; ChIP–qPCR of EZH2 occupancy and
H3K27-3me binding in the KLF2 promoter in HepG2 cells transfected with TUG1 siRNA (48 h) or scrambled siRNA. v The KLF2 expression level was
determined by qPCR in mice tumors formed from HepG2/sh-TUG1,HepG2/empty vector. w Tumors developed from sh-TUG1 transfected HepG2 cells
showed higher KLF2 protein levels than tumors developed by control cells. *P < 0.05, **P< 0.01 and N.S. not significant
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silence of KLF2 expression result in blocking the tumor-
suppressor features of KLF2, which is partly mediated by
p21 [35]. Our data also showed that TUG1 could take
part in HCC cells proliferation by silencing KLF2 tran-
scription, and KLF2 over-expression further led to the
decreased HCC cells proliferation and increased cell
apoptosis. Our results suggested that lncRNA, especiallyTUG1, may influence the same cell biological function
via regulating different target genes depending on differ-
ent cancer cells.
Conclusion
To date, the possible targets and mechanism that underlie
lncRNAs mediated regulatory behaviors still remain to be
fully investigated in different cancers. In summary, the
Fig. 5 Over-expression of KLF2 expression inhibit HepG2 cells proliferation and improve apoptosis. a The mRNA level of KLF2 in HepG2 and
Hep3B cells transfected with pCMV-Tag2B-KLF2 was detected by qPCR. b,c MTT assays and colony-forming assays were used to determine the
cell viability for pCMV-Tag2B-KLF2 -transfected HepG2 and Hep3B cells. Values represent the mean ± s.d. from three independent experiments.
d Apoptosis was determined by flow cytometry. UL, necrotic cells; UR, terminal apoptotic cells; LR, early apoptotic cells. *P < 0.05 and **P < 0.01
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Fig. 6 TUG1 negatively regulates expression of KLF2 by rescue assays. a,b Colony-forming assays were used to determine the cell viability for
HepG2 cells transfected with si-NC,si-TUG1-1# and co-transfected with si-TUG1-1# and si-KLF2. Values represent the mean ± s.d. from three
independent experiments. c MTT assays were used to determine the cell viability for HepG2 cells transfected with si-NC,si-TUG1-1# and
co-transfected with si-TUG1-1# and si-KLF2. Values represent the mean ± s.d. from three independent experiments. d,e The levels of KLF2 protein
levels were determined by Western Blotting when HepG2 cells transfected with si-NC, si-TUG1-1# and co-transfected with si-TUG1-1# and si-KLF2
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HCC tissues and cells, suggesting that its overexpression
may be an important factor for HCC progression. We
showed that TUG1 may regulates the proliferation ability
of HCC cells partially through sliencing of the KLF2 by
binding with PRC2, which suggested that lncRNAs
contribute to different cancer cells biological function
through regulating different genes. Our findings further
the understanding of HCC pathogenesis, and facilitate
the development of lncRNA-directed diagnostics and
therapeutics against this disease.
Materials and methods
Patient data and tissue samples
A total of 77 fresh HCC tissue samples and matched
normal adjacent tissue samples were selected from
patients who underwent resection of primary HCC at
Huai’an First People’s Hospital, Nanjing Medical University
(Huai’an, China). The HCC diagnosis was histopathologic-
ally confirmed. None of the patients received preoperative
therapy. Data from all subjects were obtained from medical
records, pathology reports, and personal interviews with
the subjects. The collected data included age, gender, drink-
ing state, the history of HBV and cirrosis and HCC features(e.g., tumor size, stage). HCC clinical stage was determined
according to the BCLC staging classification based on the
article by Bruix and Llovet [36]. The clinical information
for all of the samples is detailed in Table 1. Fresh samples
were snap-frozen in liquid nitrogen immediately after
resection and stored at −80 °C. Matched nontumor speci-
mens were obtained from a part of the resected specimen
that was farthest from the cancer.Ethical approval of the study protocol
This study was conducted according to the principles
expressed in the Declaration of Helsinki. Tissue speci-
men collections were made with full informed consent
of the patients, and followed institutional ethical guide-
lines that were reviewed and approved by Huai’an First
People’s Hospital, Nanjing Medical University (Huai’an,
China).Cell culture
Human HCC cell lines (HepG2, MHCC-97H, Hep3B) and
one normal hepatic epithelial cell line (L02, control) were
provided by Dr Beicheng Sun from the Department of
Hepatopancreatobiliary, First Affiliated Hospital, Nanjing
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China). All cell lines were cultured in DMEM (GIBCO-
BRL) medium supplemented with 10 % fetal bovine serum
(FBS) at 37 °C in 5 % CO2.
RNA extraction and qPCR analysis
The total RNA was extracted from tissues or cultured cells
with TRIzol reagent (Invitrogen, Grand Island, NY, USA),
according to the manufacturer’s protocol. One microgram
total RNA was reverse transcribed in a final volume of
20 μL under standard conditions using PrimeScript RT
Reagent Kit with gDNA Eraser (Takara, Dalian, China;
RR047A). After the RT reaction, 1 μL of the complemen-
tary DNA was used for subsequent qPCR reactions (SYBR
Premix Ex Taq, TaKaRa) following the manufacturer’s
protocol. The results were normalized to the expression of
GAPDH. The qPCR and data collection were carried out
on ABI 7500 real-time PCR system (Applied Biosystems,
Foster City, CA, USA), and results were analyzed and
expressed relative to threshold cycle(CT) values, and then
converted to fold changes. All primer sequences are sum-
marized in Additional file 1: Table S1.
Transfection of cell lines
HCC cell lines were transfected with specific siRNA
oligonucleotidesby using Lipofectamine RNAi MAX,
according to the manufacturer’s protocol (Invitrogen).
TUG1 siRNA, to avoid off-target effects and ensure the
efficiency of interference, we used two indeed effective
interference target sequence of TUG1, according to
previous study [19]. EZH2 siRNA was purchased from
Realgene (Nanjing, China). Non-specific siRNA (si-NC)
was purchased from Invitrogen. Typically, cells were
seeded at six-well plates and then transfected the next day
with specific siRNA (100 nM) and control siRNA
(100 nM). EGFP-SP1 was purchased from Add gene. Plas-
mid vectors (EGFP-SP1, sh-TUG1 pCMV-Tag2B-FLAG-
KLF2 and empty vector) for transfection were prepared
using DNA Midiprep or Midiprep kits (Qiagen, Hilden,
Germany), and transfected into HepG2 and Hep3B cells.
Cell proliferation assays
Cell proliferation was monitored by Cell Proliferation
Reagent Kit I (MTT) (Roche, Basel, Switzerland). The
transfected cells were plated in 96-well plates (3000 cells/
well). Cell proliferation was determined every 24 h follow-
ing the manufacturer’s protocol. For the colony-formation
assay, 500 transfected cells were placed into each well of a
six-well plate and maintained in DMEM containing 12 %
FBS for 12 days, replacing the medium every 4 days. Col-
onies were fixed with methanol and stained with 0.1 %
crystal violet (Sigma-Aldrich, St. Louis, MO, USA) in PBS
for 15 min. The colony formation was determined bycounting the number of stained colonies. Triplicate wells
were measured in each treatment group.
Flow cytometry for cell cycle analysis
HepG2 or Hep3B cells for cell cycle analysis were col-
lected 24 h after transfected with si-TUG1 or respective
control, 48 h after transfected with pCMV-Tag2B-KLF2 or
empty vector. Then cells were stained with PI using the
CycleTEST™ PLUS DNA Reagent Kit (BD Biosciences) ac-
cording to the protocol and analyzed by FACScan. The
percentage of the cells in G0/G1, S, and G2/M phase were
counted and compared.
Flow cytometry for cell apoptosis analysis
HepG2 or Hep3B cells transfected with si-TUG1, pCMV-
Tag2B-KLF2 or respective control were harvested 48 h
and then collected. After the double staining with
FITC-Annexin V and Propidium iodide (PI) was done
using the FITC Annexin V Apoptosis Detection Kit
(BD, Biosciences) according to the manufacturer’s proto-
col, the cells were analyzed with a flow cytometry (FACS-
can®; BD Biosciences) equipped with a CellQuest software
(BD Biosciences). Cells were discriminated into viable
cells, dead cells, early apoptotic cells, and apoptotic cells,
and then the relative ratio of early apoptotic cells were
compared to control transfectant from each experiment.
Cell migration and invasion assays
HepG2 or Hep3B cells transfected with si-TUG1or respect-
ive control were harvested 48 h and then collected. For the
migration assays, 5 × 104 cells in serum-free medium were
placed into the upper chamber of an insert (8 μm pore size;
Millipore). For the invasion assays, 1 × 105 cells in serum-
free medium were placed into the upper chamber of an
insert coated with Matrigel (Sigma-Aldrich). Medium
containing 10 % FBS was added to the lower chamber.
After incubation for 24 h, we removed the cells remaining
on the upper membrane with cotton wool. Cells that had
migrated or invaded through the membrane were stained
with methanol and 0.1 % crystal violet, imaged, and
counted using an IX71 inverted microscope (Olympus,
Tokyo, Japan). Experiments were repeated three times.
Xenograft study
HepG2 cells were transfected with sh-TUG1 or Scramble
using Lipofectamine 2000 (Invitrogen). After 48 h,
cells were collected and injected into either side of the
posterior flank of the male BALB/c nude mice (4–5
weeks old). Mice were purchased from Shanghai
Experimental Animal Center of the Chinese Academy
of Sciences. The tumor volumes and weights were mea-
sured every 4 days in mice from the control (5 mice) or
sh-TUG1 (5 mice) groups, and tumor volumes were calcu-
lated by using the equation V = 0.5 × D × d2 (V, volume; D,
Huang et al. Molecular Cancer  (2015) 14:165 Page 11 of 12longitudinal diameter; d, latitudinal diameter). Sixteen days
after injection, the mice were killed and tumor weights
were measured and used for further analysis. This study
was carried out strictly in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol
was approved by the Committee on the Ethics of Animal
Experiments of Nanjing Medical University.
Immunohistochemistry
Tumors from mice were immunostained for HE, ki-67
and KLF2. The signal was amplified and visualized with
3′-diaminobenzidine chromogen, followed by counter-
staining with hematoxylin. Expression was considered to
be positive when 50 % or more tumor cells were stained.
Anti-ki-67(1:50) and anti-KLF2(1:50) were purchased
from R&D company.
Western blot assay
The cells were lysed by using mammalian protein extrac-
tion reagent RIPA (Beyotime, Haimen, China) supple-
mented with protease inhibitors cocktail (Roche). Fifty
micrograms of the protein extractions were separated by
10 % SDS-PAGE transferred to 0.22 mm nitrocellulose
(NC) membranes (Sigma-Aldrich) and incubated with
specific antibodies. The autoradiograms were quantified by
densitometry (Quantity One software; Bio-Rad, Hercules,
CA, USA). Anti-KLF2 was purchased from Sigma (1:1000).
Results were normalized to the expression β-actin (Mouse
anti-β-actin) (Sigma (1:1000)).
Subcellular fractionation location
The separation of the nuclear and cytosolic fractions of
HCC cell lines was performed according to the protocol
of the PARIS Kit (Life Technologies, Carlsbad, CA, USA).
Chromatin immunoprecipitation assays(ChIP)
The ChIP assays were performed by using EZ-ChIP KIT
according to the manufacturer’s instruction (Millipore,
Billerica, MA, USA). HepG2 or Hep3B cells were
treated with formaldehyde and incubated for 10 min
to generate DNA-protein cross-links. Cell lysates were then
sonicated to generate chromatin fragments of 200–300 bp
and immunoprecipitated with EZH2 and H3K27me3-
specific antibody (CST) or IgG as control. Precipitated
chromatin DNA was recovered and analyzed by qPCR.
RNA immunoprecipitation(RIP)
RIP experiments were performed by using a Magna RIP
RNA-Binding Protein Immunoprecipitation Kit (Millipore)
according to the manufacturer’s instructions. Antibody for
RIP assays of EZH2 and SUZ12 were purchased from
Millipore.Statistical analysis
All statistical analyses were performed by using SPSS 17.0
software (IBM, Chicago, IL, USA). The significance of dif-
ferences between groups was estimated by the Student
t-test, Wilcoxon test or χ2 test. Two-sided p-values
were calculated, and differences were considered to be
statistically significant at P < 0.05. Kendall’s Tau-b and
Pearson correlation analyses were used to investigate
the correlation between TUG1 and KLF2 expressions.
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